drugset
drugset / Trial / NCT04237493

Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan

NCT04237493 ↗

Phase 4 Completed 687 enrolled University of Jordan
RandomizedParallel-groupOpen-labelTreatment

Summary

Every lunar year, during the month of Ramadan, Muslims abstain from food and drink between dawn and nightfall. People with type 2 diabetes who fast during Ramadan are at an increased risk of acute glycemic complications. Our aim is to investigate the effect of dosage reduction of four glucose-lowering multidrug regimens on the incidence of acute glycemic complications in people with type 2 diabetes who fast during Ramadan.

Timeline

Start
2017-02-14
Primary completion
2017-07-24
Completion
2017-07-24

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Glimepiride Small molecule 1.5 mg Oral
Subject Glimepiride Small molecule 2 mg Oral
Subject Glimepiride Small molecule 3 mg Oral
Subject Glimepiride Small molecule 4 mg Oral
Subject Insulin Protein / enzyme biologic 6 iu Subcutaneous
Subject Insulin Protein / enzyme biologic 7 iu Subcutaneous
Subject Insulin Protein / enzyme biologic 12 iu Subcutaneous
Subject Insulin Protein / enzyme biologic 15 iu Subcutaneous
Subject Insulin Protein / enzyme biologic 18 iu Subcutaneous
Subject Insulin Protein / enzyme biologic 28 iu Subcutaneous
Subject Insulin Protein / enzyme biologic 33 iu Subcutaneous
Subject Insulin Protein / enzyme biologic 40 iu Subcutaneous
Subject Metformin Small molecule 850 mg Oral
Subject Vildagliptin Other / unclassified 50 mg Oral
Subject insulin glargine Protein / enzyme biologic 6 iu Subcutaneous
Subject insulin glargine Protein / enzyme biologic 8 iu Subcutaneous
Subject insulin glargine Protein / enzyme biologic 9 iu Subcutaneous
Subject insulin glargine Protein / enzyme biologic 11 iu Subcutaneous
Subject insulin glargine Protein / enzyme biologic 33 iu Subcutaneous
Subject insulin glargine Protein / enzyme biologic 39 iu Subcutaneous
Subject insulin glargine Protein / enzyme biologic 44 iu Subcutaneous
Subject insulin glargine Protein / enzyme biologic 52 iu Subcutaneous

Indications

type 2 diabetes mellitus